This preliminary study investigates effects of methyl- and cyanocobala
min on circadian rhythms, well-being, alertness, and concentration in
healthy subjects. Six women (mean age 35 years) and 14 men (mean age 3
7 years) were randomly assigned to treatment for 14 days with 3 mg cya
no-(CB12) ou methylcobalamin (MB12) after 9 days of pre-treatment obse
rvation. Levels in the CB12 group increased rapidly in the first, then
slowly in the second treatment week, whereas increase in the MB12 gro
up pms linear. Urinary aMT6s excretion was reduced by both forms of vi
tamin B12 over 24 hours with a significant decrease between 0700-1100
hours, whereas urinary excretion of potassium ams significantly increa
sed between 0700-1100 hours. Activity from 2300-0700 hours increased s
ignificantly under both forms of vitamin B12. Sleep time was significa
ntly reduced under MB12 intake. In this group the change in the visual
analogue scales items ''sleep quality,'' ''concentration,'' and ''fee
ling refreshed'' between pretreatment and the first week of treatment
showed significant correlations with vitamin B12 plasma levels. Cortis
ol excretion and temperature were not affected by either medication.,
We conclude that vitamin B12 exerts a direct influence on melatonin. O
nly MB12 has a positive psychotropic alerting effect with a distributi
on of the sleep-wake cycle toward sleep reduction. (C) 1996 American C
ollege of Neuropsychopharmacology